Temsirolimus

Temsirolimus is a targeted cancer therapy that inhibits the mTOR (mammalian target of rapamycin) pathway, which is involved in cell growth and proliferation. It is used primarily to treat renal cell carcinoma (RCC) and is sometimes used off-label for other types of cancer.

Indications

-Advanced renal cell carcinoma (RCC) -May be used for other cancers based on clinical judgment and off-label use

Dosage

-Initial Dose: 25 mg administered intravenously (IV) once a week for 3 weeks followed by a maintenance dose. -Maintenance Dose: Adjusted based on patient tolerance and response.

Contra-Indications

-Known hypersensitivity to temsirolimus or any of its excipients. -Severe liver impairment. -Concurrent use with certain medications that are strong inducers or inhibitors of CYP3A4.

Special Precautions

-Monitor for signs of infections and neutropenia. -Regular liver function tests are necessary. -Caution in patients with a history of lung disease or non-infectious pneumonitis. -Avoid use in pregnant or breastfeeding women unless the benefit outweighs the risk.

Side Effects

-Common: Nausea, vomiting, diarrhea, anemia, and fatigue. -Serious: Hepatotoxicity, infections, pneumonitis, and hyperglycemia.

Drug Interactions

-May interact with drugs that are substrates, inhibitors, or inducers of CYP3A4. -Caution when used with other immunosuppressants or drugs that affect liver function.